|
|
 |
|
Viewing report
|
|
|
|
ALK-Abello A/S: SWOT Analysis & Company Profile
Business Review, Sep 2010, Pages: 23
Synopsis
Business Review’s ALK-Abello A/S contains a company overview, key facts, locations and subsidiaries, news and events as well as a SWOT analysis of the company.
Summary
This SWOT Analysis company profile is a crucial resource for industry executives and anyone looking to quickly understand the key information concerning ALK-Abello A/S’s business.
Business Review’s “ALK-Abello A/S SWOT Analysis & Company Profile” reports utilize a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format.
Business Review strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Scope
- Examines and identifies key information and issues about (ALK-Abello A/S) for business intelligence requirements
- Studies and presents ALK-Abello A/S’s strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported.
- The profile contains business operations, the company history, major products and services, prospects, key competitors, structure and key employees, locations and subsidiaries.
Reasons To Buy
- Quickly enhance your understanding of the company.
- Obtain details and analysis of the market and competitors as well as internal and external factors which could impact the industry.
- Increase business/sales activities by understanding your competitors’ businesses better.
- Recognize potential partnerships and suppliers.
- Obtain yearly profitability figures
Key Highlights
ALK-Abello A/S (ALK) is a pharmaceutical company engaged in developing products for allergy treatment, diagnosis and prevention. The company is principally focused on developing allergy vaccination (immunotherapy). ALK is the first company to introduce tablet based allergy vaccines. GRAZAX is the first tablet-based allergy vaccine developed by the company. ALK’s product portfolio comprises of Allergy diagnostics products (Soluprick SQ), Emergency treatment products (EpiPen) and Allergy vaccines. Further, the company offers three types of allergy vaccines, namely, tablet vaccines (GRAZAX), sublingual vaccines (SLITone), and subcutaneous vaccines (Alutard SQ). The company has five tablet-based vaccines, Grass, House dust mites, Ragweed, Tree, and Cat tablets under clinical development. ALK through its subsidiaries has its operations spread across 13 countries in the world. The company is headquartered in Horsholm, Denmark.
|
|
|
|
